Cover Image
市場調查報告書

分子診斷市場:各產品、各檢驗場所 (PoC、中央檢驗室)、各技術 (PCR、In situ 雜合反應、INAAT、微陣列、MS、NGS、TMA)、各用途、各市場區隔的預測

Molecular Diagnostics Market Analysis By Product, By Test Location (Poc, Central Lab), By Technology (PCR, In-Situ Hybridization, INAAT, Microarrays, MS, NGS, TMA), By Application (Oncology, Breast, Prostate, Others), And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 355233
出版日期 內容資訊 英文 78 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
分子診斷市場:各產品、各檢驗場所 (PoC、中央檢驗室)、各技術 (PCR、In situ 雜合反應、INAAT、微陣列、MS、NGS、TMA)、各用途、各市場區隔的預測 Molecular Diagnostics Market Analysis By Product, By Test Location (Poc, Central Lab), By Technology (PCR, In-Situ Hybridization, INAAT, Microarrays, MS, NGS, TMA), By Application (Oncology, Breast, Prostate, Others), And Segment Forecasts To 2024
出版日期: 2016年09月13日 內容資訊: 英文 78 Pages
簡介

本報告提供全球分子診斷市場相關調查分析,概要,各市場區隔預測,加上競爭情形,主要企業等系統性資訊。

第1章 摘要整理

第2章 市場概述

第3章 市場變化,趨勢,範圍

  • 市場區隔、範圍
  • 普及率、成長預測
  • SWOT分析 (各要因)
  • 波特的五力分析

第4章 市場區隔:各產品、趨勢分析

  • 產品趨勢分析
  • 設備
  • 試劑
  • 其他

第5章 市場區隔:各檢驗場所、趨勢分析

  • 趨勢分析
  • 照護現場 (PoC)
  • 自診斷或OTC
  • 中央檢驗室

第6章 市場區隔:各技術,趨勢分析

  • 趨勢分析
  • 聚合酵素鏈鎖反應 (PCR)
  • In situ 雜合反應
  • INNAT
  • 晶片、微陣列
  • 質譜分析
  • 定序
  • TMA
  • 其他

第7章 市場區隔:各用途,趨勢分析

  • 趨勢分析
  • 腫瘤
  • 藥理基因學
  • 感染疾病
  • 遺傳基因檢驗
  • 神經疾病
  • 心血管疾病
  • 微生物

第8章 市場區隔:各地區,趨勢分析 (各產品,各檢驗場所,各技術、用途)

  • 各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭情形

  • 策略性組成架構
  • 市場進入的分類
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 978-1-68038-086-6

Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.

Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also projected to positively impact the growth.

Further key findings from the study suggest:

The overall market is dominated by reagents with revenue generation of over USD 2.3 billion in 2015 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols further contributing toward the dominance of this segment.

Instruments, such as PCR and next generation sequencing platforms, are being widely preferred by central laboratories and diagnostic institutes due to the rapid nature of these tests in delivering quick & reliable results and the high volume of diagnostic procedures in this segment. Thus, this segment is expected to maintain a constant growth at a CAGR of around 9.0%.

Central laboratories led the global molecular diagnostics market by test location with revenue generation of around USD 4.0 billion in 2015 owing to their established base in the remote and developing regions

On the other hand, the point of care devices segment witnessed the fastest growth with a CAGR of over 14.0%. The associated advantages include the user-friendly nature of these tests and quick healthcare delivery, which are estimated to propel the molecular diagnostics market.

Infectious diseases held the largest share of over USD 2.9 billion in 2015. Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in short time while delivering highly accurate results. Initiatives led by organizations, such as the WHO, in conducting diagnostic programs in regions with high risk areas is estimated to be a high rendering driver.

The oncology segment is expected to exhibit a CAGR of around 13.0% over the forecast period. Rising awareness levels among people as well as healthcare professionals for cancer diagnosis is a key attribute propelling the market growth.

The PCR segment dominated the market with revenue generation of over USD 2.6 billion in 2015, attributable to the growing applications of multiplex PCR over the conventional PCR procedure and the introduction of easy-to-use PCR handling kits.

North America was observed to be the largest regional segment in 2015 with a share of over 45.0%. Key factors contributing toward the large share are well-established healthcare infrastructure, rising healthcare spending, increasing awareness levels among patients, and expansion of R&D activities related to drug discovery and development.

Asia Pacific is identified as a lucrative segment with a CAGR of approximately 17.0% over the forecast period. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth.

Some of the major players include Novartis AG (Grifols), Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc., Alere, Inc., Danaher Corporation, bioMerieux SA, Sysmex Corporation, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Bayer AG, Qiagen, Hologic, Inc. (Gen Probe), Cepheid, F. Hoffmann-La Roche Ltd, and Dako

The key players are advancing strategic collaborations with major technology-based companies & diagnostic centers and expanding into the developing regions in an attempt to increase their market share and attain stability

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Market Snapshot

Chapter 3: Market Variables, Trends & Scope

  • 3.1. Market segmentation & scope
    • 3.1.1. Market Driver Analysis
      • 3.1.1.1. Introduction of technological advancements
      • 3.1.1.2. Increasing demand for point of care facilities
      • 3.1.1.3. Growing prevalence of target diseases
      • 3.1.1.4. External funding for executing research and development exercises
    • 3.1.2. Market Restraint Analysis
      • 3.1.2.1. Presence of ambiguous regulatory framework
      • 3.1.2.2. High prices of IVD diagnostic tests
  • 3.2. Penetration & growth prospect mapping
  • 3.3. Molecular Diagnostics-SWOT Analysis, By Factor(political & legal, economic and technological)
  • 3.4. Industry Analysis-Porter's

Chapter 4: Market Categorization 1: Product Estimates & Trend Analysis

  • 4.1. Molecular diagnostics market: Product movement analysis
  • 4.2. Instruments
    • 4.2.1. Instruments market, 2013-2024(USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents market, 2013-2024(USD Million)
  • 4.4. Others
    • 4.4.1. Others market, 2013-2024(USD Million)

Chapter 5: Market Categorization 2: Test Location Estimates & Trend Analysis

  • 5.1. Molecular diagnostics market: Test Location movement analysis
  • 5.2. Point of Care(PoC)
    • 5.2.1. PoC market, 2013-2024(USD Million)
  • 5.3. Self Test or Over The Counter(OTC)
    • 5.3.1. Self Test or OTC market, 2013-2024(USD Million)
  • 5.4. Central Laboratories
    • 5.4.1. Central laboratories market, 2013-2024(USD Million)

Chapter 6: Market Categorization 3: Technology Estimates & Trend Analysis

  • 6.1. Molecular diagnostics market: Technology movement analysis
  • 6.2. Polymerase Chain Reaction(PCR)
    • 6.2.1. PCR market, 2013-2024(USD Million)
    • 6.2.2. Multiplex PCR market, 2013-2024(USD Million)
    • 6.2.3. Other PCR market, 2013-2024(USD Million)
  • 6.3. In Situ Hybridization
    • 6.3.1. In Situ Hybridization market, 2013-2024(USD Million)
  • 6.4. Isothermal Nucleic Acid Amplification Technology(INAAT)
    • 6.4.1. INAAT market, 2013-2024(USD Million)
  • 6.5. Chips and Microarrays
    • 6.5.1. Chips and microarrays market, 2013-2024(USD Million)
  • 6.6. Mass Spectrometry
    • 6.6.1. Mass spectrometry market, 2013-2024(USD Million)
  • 6.7. Sequencing
    • 6.7.1. Sequencing market, 2013-2024(USD Million)
  • 6.8. Transcription Mediated Amplification(TMA)
    • 6.8.1. TMA market, 2013-2024(USD Million)
  • 6.9. Others
    • 6.9.1. Others market, 2013-2024(USD Million)

Chapter 7: Market Categorization 4: Application Estimates & Trend Analysis

  • 7.1. Molecular diagnostics market: Application movement analysis
  • 7.2. Oncology
    • 7.2.1. Oncology market, 2013-2024(USD Million)
    • 7.2.2. Breast Cancer market, 2013-2024(USD Million)
    • 7.2.3. Prostate Cancer market, 2013-2024(USD Million)
    • 7.2.4. Colorectal Cancer market, 2013-2024(USD Million)
    • 7.2.5. Cervical Cancer market, 2013-2024(USD Million)
    • 7.2.6. Kidney Cancer market, 2013-2024(USD Million)
    • 7.2.7. Liver Cancer market, 2013-2024(USD Million)
    • 7.2.8. Blood Cancer market, 2013-2024(USD Million)
    • 7.2.9. Lung Cancer market, 2013-2024(USD Million)
    • 7.2.10. Others market, 2013-2024(USD Million)
  • 7.3. Pharmacogenomics
    • 7.3.1. Pharmacogenomics market, 2013-2024(USD Million)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious diseases market, 2013-2024(USD Million)
    • 7.4.2. Methicillin-resistant Staphylococcus Aureus(MRSA) market, 2013-2024(USD Million)
    • 7.4.3. Clostridium difficile market, 2013-2024(USD Million)
    • 7.4.4. Vancomycin-resistant enterococci market, 2013-2024(USD Million)
    • 7.4.5. Carbapenem-resistant bacteria market, 2013-2024(USD Million)
    • 7.4.6. Flu market, 2013-2024(USD Million)
    • 7.4.7. Respiratory syncytial virus(RSV) market, 2013-2024(USD Million)
    • 7.4.8. Candida market, 2013-2024(USD Million)
    • 7.4.9. Tuberculosis and drug-resistant TB market, 2013-2024(USD Million)
    • 7.4.10. Meningitis market, 2013-2024(USD Million)
    • 7.4.11. Gastrointestinal panel market, 2013-2024(USD Million)
    • 7.4.12. Chlamydia market, 2013-2024(USD Million)
    • 7.4.13. Gonorrhea market, 2013-2024(USD Million)
    • 7.4.14. HIV market, 2013-2024(USD Million)
    • 7.4.15. Hepatitis C market, 2013-2024(USD Million)
    • 7.4.16. Hepatitis B market, 2013-2024(USD Million)
    • 7.4.17. Others market, 2013-2024(USD Million)
  • 7.5. Genetic testing
    • 7.5.1. Genetic testing market, 2013-2024(USD Million)
    • 7.5.2. Newborn screening market, 2013-2024(USD Million)
    • 7.5.3. Predictive and presymptomatic testing market, 2013-2024(USD Million)
    • 7.5.4. Other market, 2013-2024(USD Million)
  • 7.6. Neurological diseases
    • 7.6.1. Neurological diseases market, 2013-2024(USD Million)
  • 7.7. Cardiovascular diseases
    • 7.7.1. Cardiovascular diseases market, 2013-2024(USD Million)
  • 7.8. Microbiology
    • 7.8.1. Microbiology market, 2013-2024(USD Million)

Chapter 8: Market Categorization 5: Regional Estimates & Trend Analysis, by Product, Test Location, Technology & Application

  • 8.1. Molecular diagnostics market share by region, 2013 & 2024
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. UK
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Belgium
    • 8.3.7. Switzerland
    • 8.3.8. Netherlands
    • 8.3.9. Poland
    • 8.3.10. Austria
    • 8.3.11. Greece
    • 8.3.12. Sweden
    • 8.3.13. Turkey
    • 8.3.14. Finland
  • 8.4. Asia Pacific
    • 8.4.1. India
    • 8.4.2. China
    • 8.4.3. Japan
    • 8.4.4. Sri Lanka
    • 8.4.5. Malaysia
    • 8.4.6. Australia
    • 8.4.7. New Zealand
    • 8.4.8. Thailand
    • 8.4.9. Vietnam
    • 8.4.10. Ireland
    • 8.4.11. Singapore
  • 8.5. Latin America
    • 8.5.1. Mexico
    • 8.5.2. Brazil
    • 8.5.3. Chile
    • 8.5.4. Peru
    • 8.5.5. Colombia
    • 8.5.6. Argentina
  • 8.6. MEA
    • 8.6.1. South Africa
    • 8.6.2. Saudi Arabia
    • 8.6.3. Jordan
    • 8.6.4. UAE
    • 8.6.5. Qatar
    • 8.6.6. Nigeria
    • 8.6.7. Egypt

Chapter 9: Competitive Landscape

  • 9.1. Strategy framework
  • 9.2. Market participation categorization
  • 9.3. Company Profiles
    • 9.3.1. Abbott Molecular
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Alere, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Bayer Healthcare AG
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Becton, Dickinson and Company
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. bioMerieux SA
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bio-Rad Laboratories, Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Cepheid
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Dako
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Beckman Coulter
      • 9.3.9.3. Leica Biosystems
      • 9.3.9.4. Financial Performance
      • 9.3.9.5. Product Benchmarking
      • 9.3.9.6. Strategic Initiatives
      • 9.3.9.7. Strategic Initiatives of Beckman Coulter Inc.
      • 9.3.9.8. Strategic Initiatives of Leica Biosystems
    • 9.3.10. Hologic, Inc.(Gen Probe)
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Johnson & Johnson Services, Inc.
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Novartis AG(Grifols)
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Product Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Qiagen
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Product Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. F. Hoffmann-La Roche Ltd
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Product Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Siemens Healthcare GmbH
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Product Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. Sysmex Corporation
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Product Benchmarking
      • 9.3.16.4. Strategic Initiatives

List of Tables

  • TABLE 1: North America molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 2: North America molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 3: North America molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 4: North America PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 5: North America molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 6: North America oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 7: North America infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 8: North America genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 9: U.S. molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 10: U.S. molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 11: U.S. molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 12: U.S. PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 13: U.S. molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 14: U.S. oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 15: U.S. infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 16: U.S. genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 17: Canada molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 18: Canada molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 19: Canada molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 20: Canada PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 21: Canada molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 22: Canada oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 23: Canada infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 24: Canada genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 25: Europe molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 26: Europe molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 27: Europe molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 28: Europe PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 29: Europe molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 30: Europe oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 31: Europe infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 32: Europe genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 33: UK molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 34: UK molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 35: UK molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 36: UK PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 37: UK molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 38: UK oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 39: UK infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 40: UK genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 41: Germany molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 42: Germany molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 43: Germany molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 44: Germany PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 45: Germany molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 46: Germany oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 47: Germany infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 48: Germany genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 49: France molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 50: France molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 51: France molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 52: France PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 53: France molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 54: France oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 55: France infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 56: France genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 57: Italy molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 58: Italy molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 59: Italy molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 60: Italy PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 61: Italy molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 62: Italy oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 63: Italy infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 64: Italy genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 65: Spain molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 66: Spain molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 67: Spain molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 68: Spain PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 69: Spain molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 70: Spain oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 71: Spain infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 72: Spain genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 73: Belgium molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 74: Belgium molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 75: Belgium molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 76: Belgium PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 77: Belgium molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 78: Belgium oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 79: Belgium infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 80: Belgium genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 81: Switzerland molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 82: Switzerland molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 83: Switzerland molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 84: Switzerland PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 85: Switzerland molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 86: Switzerland oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 87: Switzerland infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 88: Switzerland genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 89: Netherlands molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 90: Netherlands molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 91: Netherlands molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 92: Netherlands PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 93: Netherlands molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 94: Netherlands oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 95: Netherlands infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 96: Netherlands genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 97: Poland molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 98: Poland molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 99: Poland molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 100: Poland PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 101: Poland molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 102: Poland oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 103: Poland infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 104: Poland genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 105: Austria molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 106: Austria molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 107: Austria molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 108: Austria PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 109: Austria molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 110: Austria oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 111: Austria infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 112: Austria genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 113: Greece molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 114: Greece molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 115: Greece molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 116: Greece PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 117: Greece molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 118: Greece oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 119: Greece infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 120: Greece genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 121: Sweden molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 122: Sweden molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 123: Sweden molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 124: Sweden PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 125: Sweden molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 126: Sweden oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 127: Sweden infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 128: Sweden genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 129: Turkey molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 130: Turkey molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 131: Turkey molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 132: Turkey PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 133: Turkey molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 134: Turkey oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 135: Turkey infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 136: Turkey genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 137: Finland molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 138: Finland molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 139: Finland molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 140: Finland PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 141: Finland molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 142: Finland oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 143: Finland infectious disease market, by application, 2013 - 2024 (USD Million)
  • TABLE 144: Finland genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 145: Asia Pacific molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 146: Asia Pacific molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 147: Asia Pacific molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 148: Asia Pacific PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 149: Asia Pacific molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 150: Asia Pacific oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 151: Asia Pacific infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 152: Asia Pacific genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 153: India molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 154: India molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 155: India molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 156: India PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 157: India molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 158: India oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 159: India infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 160: India genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 161: China molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 162: China molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 163: China molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 164: China PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 165: China molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 166: China oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 167: China infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 168: China genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 169: Japan molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 170: Japan molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 171: Japan molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 172: Japan PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 173: Japan molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 174: Japan oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 175: Japan infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 176: Japan genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 177: Sri Lanka molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 178: Sri Lanka molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 179: Sri Lanka molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 180: Sri Lanka PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 181: Sri Lanka molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 182: Sri Lanka oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 183: Sri Lanka infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 184: Sri Lanka genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 185: Malaysia molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 186: Malaysia molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 187: Malaysia molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 188: Malaysia PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 189: Malaysia molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 190: Malaysia oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 191: Malaysia infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 192: Malaysia genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 193: Australia molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 194: Australia molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 195: Australia molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 196: Australia PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 197: Australia molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 198: Australia oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 199: Australia infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 200: Australia genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 201: New Zealand molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 202: New Zealand molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 203: New Zealand molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 204: New Zealand PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 205: New Zealand molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 206: New Zealand oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 207: New Zealand infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 208: New Zealand genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 209: Thailand molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 210: Thailand molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 211: Thailand molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 212: Thailand PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 213: Thailand molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 214: Thailand oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 215: Thailand infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 216: Thailand genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 217: Vietnam molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 218: Vietnam molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 219: Vietnam molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 220: Vietnam PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 221: Vietnam molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 222: Vietnam oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 223: Vietnam infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 224: Vietnam genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 225: Ireland molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 226: Ireland molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 227: Ireland molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 228: Ireland PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 229: Ireland molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 230: Ireland oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 231: Ireland infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 232: Ireland genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 233: Singapore molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 234: Singapore molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 235: Singapore molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 236: Singapore PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 237: Singapore molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 238: Singapore oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 239: Singapore infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 240: Singapore genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 241: Latin America molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 242: Latin America molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 243: Latin America molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 244: Latin America PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 245: Latin America molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 246: Latin America oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 247: Latin America infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 248: Latin America genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 249: Mexico molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 250: Mexico molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 251: Mexico molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 252: Mexico PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 253: Mexico molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 254: Mexico oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 255: Mexico infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 256: Mexico genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 257: Brazil molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 258: Brazil molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 259: Brazil molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 260: Brazil PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 261: Brazil molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 262: Brazil oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 263: Brazil infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 264: Brazil genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 265: Chile molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 266: Chile molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 267: Chile molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 268: Chile PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 269: Chile molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 270: Chile oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 271: Chile infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 272: Chile genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 273: Peru molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 274: Peru molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 275: Peru molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 276: Peru PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 277: Peru molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 278: Peru oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 279: Peru infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 280: Peru genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 281: Colombia molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 282: Colombia molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 283: Colombia molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 284: Colombia PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 285: Colombia molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 286: Colombia oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 287: Colombia infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 288: Colombia genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 289: Argentina molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 290: Argentina molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 291: Argentina molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 292: Argentina PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 293: Argentina molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 294: Argentina oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 295: Argentina infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 296: Argentina genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 297: MEA molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 298: MEA molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 299: MEA molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 300: MEA PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 301: MEA molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 302: MEA oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 303: MEA infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 304: MEA genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 305: South Africa molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 306: South Africa molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 307: South Africa molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 308: South Africa PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 309: South Africa molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 310: South Africa oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 311: South Africa infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 312: South Africa genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 313: Saudi Arabia molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 314: Saudi Arabia molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 315: Saudi Arabia molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 316: Saudi Arabia PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 317: Saudi Arabia molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 318: Saudi Arabia oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 319: Saudi Arabia infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 320: Saudi Arabia genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 321: Jordan molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 322: Jordan molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 323: Jordan molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 324: Jordan PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 325: Jordan molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 326: Jordan oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 327: Jordan infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 328: Jordan genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 329: UAE molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 330: UAE molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 331: UAE molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 332: UAE PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 333: UAE molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 334: UAE oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 335: UAE infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 336: UAE genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 337: Qatar molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 338: Qatar molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 339: Qatar molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 340: Qatar PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 341: Qatar molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 342: Qatar oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 343: Qatar infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 344: Qatar genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 345: Nigeria molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 346: Nigeria molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 347: Nigeria molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 348: Nigeria PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 349: Nigeria molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 350: Nigeria oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 351: Nigeria infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 352: Nigeria genetic testing market, by application, 2013 - 2024 (USD Million)
  • TABLE 353: Egypt molecular diagnostics market, by product, 2013 - 2024 (USD Million)
  • TABLE 354: Egypt molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
  • TABLE 355: Egypt molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 356: Egypt PCR market, by segment, 2013 - 2024 (USD Million)
  • TABLE 357: Egypt molecular diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 358: Egypt oncology market, by application, 2013 - 2024 (USD Million)
  • TABLE 359: Egypt infectious diseases market, by application, 2013 - 2024 (USD Million)
  • TABLE 360: Egypt genetic testing market, by application, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market trends & outlook
  • FIG. 3: Market segmentation & scope
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restrain relevance analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8: Porter's Five Forces Analysis
  • FIG. 9: Molecular diagnostics market product outlook key takeaways
  • FIG. 10: Molecular diagnostics market: Product movement analysis
  • FIG. 11: Global Instruments market, 2013 - 2024 (USD Million)
  • FIG. 12: Global Reagents market, 2013 - 2024 (USD Million)
  • FIG. 13: Global Others market, 2013 - 2024 (USD Million)
  • FIG. 14: Molecular diagnostics market test location outlook: Key takeaways
  • FIG. 15: Molecular diagnostics market: Test Location movement analysis
  • FIG. 16: Global PoC market, 2013 - 2024 (USD Million)
  • FIG. 17: Global Self Test or OTC market, 2013 - 2024 (USD Million)
  • FIG. 18: Global Central laboratories market, 2013 - 2024 (USD Million)
  • FIG. 19: Molecular diagnostics market technology outlook: Key takeaways
  • FIG. 20: Molecular diagnostics market: Technology movement analysis
  • FIG. 21: Global PCR market, 2013 - 2024 (USD Million)
  • FIG. 22: Global Multiplex PCR market, 2013 - 2024 (USD Million)
  • FIG. 23: Global Other PCR market, 2013 - 2024 (USD Million)
  • FIG. 24: Global In Situ Hybridization market, 2013 - 2024 (USD Million)
  • FIG. 25: Global INAAT market, 2013 - 2024 (USD Million)
  • FIG. 26: Global Chips and microarrays market, 2013 - 2024 (USD Million)
  • FIG. 27: Global Mass spectrometry market, 2013 - 2024 (USD Million)
  • FIG. 28: Global Sequencing market, 2013 - 2024 (USD Million)
  • FIG. 29: Global TMA market, 2013 - 2024 (USD Million)
  • FIG. 30: Global Other market, 2013 - 2024 (USD Million)
  • FIG. 31: Molecular diagnostics market application outlook: Key takeaways
  • FIG. 32: Molecular diagnostics market: Application movement analysis
  • FIG. 33: Global Oncology market, 2013 - 2024 (USD Million)
  • FIG. 34: Global Breast Cancer market, 2013 - 2024 (USD Million)
  • FIG. 35: Global Prostate Cancer market, 2013 - 2024 (USD Million)
  • FIG. 36: Global Colorectal Cancer market, 2013 - 2024 (USD Million)
  • FIG. 37: Global CervicalCancer market, 2013 - 2024 (USD Million)
  • FIG. 38: Global KidneyCancer market, 2013 - 2024 (USD Million)
  • FIG. 39: Global LiverCancer market, 2013 - 2024 (USD Million)
  • FIG. 40: Global BloodCancer market, 2013 - 2024 (USD Million)
  • FIG. 41: Global LungCancer market, 2013 - 2024 (USD Million)
  • FIG. 42: Global Other market, 2013 - 2024 (USD Million)
  • FIG. 43: Global Pharmacogenomics market, 2013 - 2024 (USD Million)
  • FIG. 44: Global Infectious diseases market, 2013 - 2024 (USD Million)
  • FIG. 45: Global MRSA market, 2013 - 2024 (USD Million)
  • FIG. 46: Global Clostridium difficile market, 2013 - 2024 (USD Million)
  • FIG. 47: Global Vancomycin-resistant enterococci market, 2013 - 2024 (USD Million)
  • FIG. 48: Global Carbapenem-resistant bacteria market, 2013 - 2024 (USD Million)
  • FIG. 49: Global Flu market, 2013 - 2024 (USD Million)
  • FIG. 50: Global RSV market, 2013 - 2024 (USD Million)
  • FIG. 51: Global Candida market, 2013 - 2024 (USD Million)
  • FIG. 52: Global Tuberculosis and drug-resistant TB market, 2013 - 2024 (USD Million)
  • FIG. 53: Global Meningitis market, 2013 - 2024 (USD Million)
  • FIG. 54: Global Gastrointestinal panel market, 2013 - 2024 (USD Million)
  • FIG. 55: Global Chlamydia market, 2013 - 2024 (USD Million)
  • FIG. 56: Global Gonorrhea market, 2013 - 2024 (USD Million)
  • FIG. 57: Global HIV market, 2013 - 2024 (USD Million)
  • FIG. 58: Global Hepatitis C market, 2013 - 2024 (USD Million)
  • FIG. 59: Global Hepatitis B market, 2013 - 2024 (USD Million)
  • FIG. 60: Global Other market, 2013 - 2024 (USD Million)
  • FIG. 61: Global Genetic testing market, 2013 - 2024 (USD Million)
  • FIG. 62: Global Newborn screening market, 2013 - 2024 (USD Million)
  • FIG. 63: Global Predictive and presymptomatic testing market, 2013 - 2024 (USD Million)
  • FIG. 64: Global Other market, 2013 - 2024 (USD Million)
  • FIG. 65: Global Neurological diseases market, 2013 - 2024 (USD Million)
  • FIG. 66: Global Cardiovascular diseases market, 2013 - 2024 (USD Million)
  • FIG. 67: Global Microbiology market, 2013 - 2024 (USD Million)
  • FIG. 68: Regional market place: Key takeaways
  • FIG. 69: Regional outlook, 2015 & 2024
  • FIG. 70: Strategy framework
  • FIG. 71: Participant categorization
Back to Top